Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Visa to Move European Headquarters to London’s Canary Wharf 
 - EconoTimes)
NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Vital Therapies, Inc. (“Vital” or the “Company”) (Nasdaq:VTL) and certain of its present and former officers in the United District Court for the Southern District of California on behalf of a class consisting of all persons or entities who purchased Vital securities between April 17, 2014 and August 21, 2015, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that Defendants issued materially false and misleading statements and/or failed to disclose material information regarding the Company’s ELAD System studies, VTI-208, VTI-210, and VTI-212, including (i) the studies’ independent significance; (ii) the degree to which the studies were interrelated; and (iii) that in the case of the failure of the VTI-208 trial, the Company would not continue the VTI-210 trial.
On August 21, 2015, Vital announced that the VTI-208 trial had “failed to meet the primary endpoint of overall survival through at least 91 days” and that the Company would stop the VTI-210 and VTI-212 clinical trials. Upon this news, the Company shares plunged 73.4% to close at just $3.65 per share the next trading day.
If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
